CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 162 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q3 2021. The put-call ratio across all filers is 0.67 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,371,377 | -10.5% | 49,832 | +10.3% | 0.00% | 0.0% |
| Q2 2023 | $1,532,482 | -30.3% | 45,166 | -26.1% | 0.00% | 0.0% |
| Q1 2023 | $2,197,586 | -16.5% | 61,078 | +4.1% | 0.00% | -50.0% |
| Q4 2022 | $2,633,050 | +71.0% | 58,651 | +7.7% | 0.00% | +100.0% |
| Q3 2022 | $1,539,670 | +11.7% | 54,464 | +8.6% | 0.00% | 0.0% |
| Q2 2022 | $1,378,913 | -36.9% | 50,133 | -21.1% | 0.00% | 0.0% |
| Q1 2022 | $2,186,828 | +142.2% | 63,511 | +172.7% | 0.00% | 0.0% |
| Q4 2021 | $903,000 | -28.4% | 23,286 | -0.4% | 0.00% | 0.0% |
| Q3 2021 | $1,262,000 | +70.5% | 23,379 | +5.6% | 0.00% | 0.0% |
| Q2 2021 | $740,000 | – | 22,135 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 3,200,000 | $88,064,000 | 14.40% |
| Octagon Capital Advisors LP | 759,898 | $20,912,393 | 3.21% |
| TSP Capital Management Group, LLC | 251,695 | $6,926,645 | 2.67% |
| 5AM Venture Management, LLC | 310,270 | $8,538,630 | 2.46% |
| COMMODORE CAPITAL LP | 706,665 | $19,447,421 | 2.27% |
| ACUTA CAPITAL PARTNERS, LLC | 122,341 | $3,366,824 | 2.26% |
| Redmile Group, LLC | 1,635,938 | $45,021,014 | 2.14% |
| RTW INVESTMENTS, LP | 3,463,201 | $95,307,292 | 2.01% |
| Eversept Partners, LP | 588,143 | $16,185,695 | 1.37% |
| Affinity Asset Advisors, LLC | 150,000 | $4,128,000 | 1.16% |